Physician profile
Jerrell W Herod
NPI 1982870481
$9,806.63
in general payments reported to CMS, 2019-2025
51 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $653 · 2021: $971 · 2022: $1,414 · 2023: $1,986 · 2024: $1,808 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,383.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,027.76 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $999.65 | 2019-2025 | |
| Pfizer INC. | $882.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $533.85 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.04 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $490.56 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $404.36 | 2019-2025 | Wainua, Farxiga |
| Impulse Dynamics (USA) INC. | $398.26 | 2022-2023 | Optimizer |
| Cvrx, INC. | $355.06 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $352.10 | 2021-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $341.84 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $289.57 | 2019-2023 | |
| Boston Scientific Corporation | $263.75 | 2019-2024 | Watchman Access System, Varithena Administration Pack |
| Alnylam Pharmaceuticals INC. | $261.02 | 2021-2025 | Amvuttra |
| Scpharmaceuticals INC. | $254.02 | 2023-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrell Herod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.